Sub-second high dose rate brachytherapy Monte Carlo dose calculations with bGPUMCD

Purpose: To establish the accuracy and speed of bGPUMCD, a GPU-oriented Monte Carlo code used for high dose rate brachytherapy dose calculations. The first objective is to evaluate the time required for dose calculation when full Monte Carlo generated dose distribution kernels are used for plan optimization. The second objective is to assess the accuracy and speed when recalculating pre-optimized plans, consisting of many dwell positions. Methods: bGPUMCD is tested with three clinical treatment plans : one prostate case, one breast case, and one rectum case with a shielded applicator. Reference distributions, generated with GEANT4, are used as a basis of comparison. Calculations of full dose distributions of pre-optimized treatment plans as well as single dwell dosimetry are performed. Single source dosimetry, based on TG-43 parameters reproduction, is also presented for the microSelectron V2 (Nucletron, Veenendaal, The Netherlands). Results: In timing experiments, the computation of single dwell position dose kernels takes between 0.25 and 0.5 s. bGPUMCD can compute full dose distributions of previously optimized plans in similar to 2 s. bGPUMCD is capable of computing pre-optimized brachytherapy plans within 1% for the prostate case and 2% for the breast and shielded applicator cases, when comparing the dosimetric parameters D90 and V100 of the reference (GEANT4) and bGPUMCD distributions. For all voxels within the target, an absolute average difference of approximately 1% is found for the prostate case, less than 2% for the breast case and less than 2% for the rectum case with shielded applicator. Larger point differences (>5%) are found within bony regions in the prostate case, where bGPUMCD underdoses compared to GEANT4. Single source dosimetry results are mostly within 2% for the radial function and within 1%-4% for the anisotropic function. Conclusions: bGPUMCD has the potential to allow for fast MC dose calculation in a clinical setting for all phases of HDR treatment planning, from dose kernel calculations for plan optimization to plan recalculation. (C) 2012 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4730500]